TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval

Takeda announces its intention to acquire TiGenix

Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs

4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics

FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)